MiniMed Group MMED
United StatesHealthcare · Medical Instruments & SuppliesUSD
24.69 USD (+29.2%)
13 analysts
Trading 2120.30 €Open account ↗
Lightyear0.90 €Open account ↗
N260.90 €Open account ↗
XTB1.00 €★ featured · affiliateOpen account ↗Trading 2120.30 €Open account ↗Lightyear0.90 €Open account ↗XTB1.00 €★ featured · affiliateOpen account ↗200.00 € order · cheapest cheapest available in your country iCompare all 22 brokers →What does it do?
MiniMed Group, Inc. is a medical device company that designs, manufactures, and sells instruments and supplies for the healthcare sector, with a business model of high gross margins (56.89%) and double-digit revenue growth.
Key points
from its scores- ✓Strong growth7.9
- ✓Good share-price trend7.5
- ✕Little or no dividend0.5
- ✕Little competitive advantage2.8
- ✕Demanding valuation3.9
AI analysis
bottom line, main risk, context and newsGrowth and a sound balance sheet are positive, but low profitability and a high multiple require confirmation of margin improvement before buying.
MiniMed Group shows solid growth (revenue +16.60%) and a healthy financial position with net cash (Net Debt/EBITDA -0.52), but return on equity is poor (ROE -8.66%) and valuation is demanding (forward P/E 29.99), which weighs on quality and price attractiveness.
The inability to convert revenue growth into return on capital (ROE -8.66%) and free cash flow generation, which could support the current P/E of 29.99 valuation.
Context and risks
No recent news and no material exposure to current macro factors: the rise in long-term US rates and dollar strength do not directly affect a medical device maker with net cash and wide margins. The healthcare business is one of those the macro context itself identifies as having a null effect from rates and commodities.
Is MiniMed Group stock cheap or expensive?
at the analysis dateOn EV / EBITDA, it trades 26% above the Healthcare median.
| Multiple | Company | Sector | Difference |
|---|---|---|---|
| EV / EBITDA | 18.3 | 14.5 | +26% |
| Price / book | 1.5 | 4.1 | −64% |
| Price / sales | 1.7 | 3.4 | −51% |
Sector: median of the 217 Healthcare companies analysed. In bold, the multiples used for the comparison.
Valuation score: 3.9 out of 10 (median for Healthcare: 4.7).
Average analyst target: 24.69 USD, +29.2% versus the price.
A premium can be justified if the company is of higher quality or grows faster than its sector: Quality / Moat 2.8 (sector 5.5), Growth 7.9 (sector 6.6).
Work out its fair value yourself →How much would you have made investing every month? →
Comparing it with its sector does not say whether it is a good buy: this is not investment advice.
Score by category
0 to 10 · hover overtap each one to see what it measuresKey metrics
at the analysis date · compared with the Healthcare medianValuation
- Forward P/E
- 30.0
- EV / EBITDA
- 18.3
- Price / book
- 1.5
- Price / sales
- 1.7
- Market cap
- 5.4B USD
- Enterprise value
- 5.2B USD
Profitability
- ROE
- −8.7%
- ROIC (approx.)
- 0.4%
- Gross margin
- 56.9%
- Operating margin
- 0.5%
- Net margin
- −9.7%
Solvency
- Total debt
- 59.0M USD
- Net debt
- −148.0M USD
- Cash
- 207.0M USD
- EBITDA
- 286.0M USD
- Net debt / EBITDA
- −0.52
- Debt / equity
- 1.63
- Current ratio
- 1.81
- Quick ratio
- 1.26
Growth
- Revenue growth
- +16.6%
- EPS (TTM)
- −1.53 USD
- EPS (forward)
- 0.64 USD
Dividend
- Dividend yield
- 0.0%
Risk and market
- Analyst consensus
- Buy (13)
- Target price
- 24.69 USD
- 52-week range
- 10.65 – 24.43
Recent news
All MMED news →Compare it with its sector
All 217 in Healthcare →Frequently asked questions about MiniMed Group
Is MiniMed Group stock cheap or expensive?
On EV / EBITDA, it trades 26% above the Healthcare median. Valuation score: 3.9 out of 10 (median for Healthcare: 4.7). Average analyst target: 24.69 USD, +29.2% versus the price. This is not investment advice.
What score does MiniMed Group get on MeridIAn Screener?
It scores 4.6 out of 10, rank 1,845 of 2,130 (better than 13% of the companies analysed). Its strongest category is Growth (7.9) and its weakest, Dividend (0.5). Analysis of 08/10/2026.
How much is MiniMed Group worth on the stock market?
Its market capitalisation is 5.4B USD and its enterprise value, debt included, is 5.2B USD.
How much debt does MiniMed Group have?
It has more cash than debt: net cash of 148.0M USD.
Does MiniMed Group pay a dividend?
It pays no dividend, or almost none.
How has MiniMed Group stock performed over the last year?
It has risen 3.4% over the last year, excluding dividends. Over the last 52 weeks it has traded between 10.65 and 24.43 USD. Past performance does not guarantee future results.
What do analysts think of MiniMed Group?
13 analysts cover it; their average recommendation is “Buy” and their average target is 24.69 USD (+29.2% versus the price). It is an estimate, not market data.